title: Genetics of cisplatin ototoxicity: confirming the unexplained?
abstract: Replication of findings in clinical pharmacogenetic studies is essential but often neglected. The observation that TPMT and COMT genotypes, in combination with ABCC3 genotype, are predictive of ototoxicity following cisplatin treatment has been confirmed. However, translating this observation into a useful preventive strategy requires more mechanistic insight.
authors.affiliation: Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. alan.boddy@newcastle.ac.uk
authors.forename: A V
authors.initials: AV
authors.lastname: Boddy
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D002394:Catechol O-Methyltransferase / Q000235:genetics*; D002945:Cisplatin / Q000633:toxicity*; D005260:Female; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008780:Methyltransferases / Q000235:genetics*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D002394:Catechol O-Methyltransferase; D002945:Cisplatin; D008780:Methyltransferases; D027425:ATP-Binding Cassette, Sub-Family C Proteins; C114462:multidrug resistance-associated protein 3; C022745:thiopurine methyltransferase